Literature DB >> 21996132

Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.

Boris B Quednow1, Valerie Treyer, Felix Hasler, Nadja Dörig, Matthias T Wyss, Cyrill Burger, Katharina M Rentsch, Gerrit Westera, Pius August Schubiger, Alfred Buck, Franz X Vollenweider.   

Abstract

Although alterations of serotonin (5-HT) system functioning have been proposed for a variety of psychiatric disorders, a direct method quantitatively assessing 5-HT release capacity in the living human brain is still lacking. Therefore, we evaluated a novel method to assess 5-HT release capacity in vivo using dexfenfluramine challenge and [(18)F]altanserin positron emission tomography (PET). Thirteen healthy male subjects received placebo and single oral doses of 40 mg (n = 6) or 60 mg (n = 7) of the potent 5-HT releaser dexfenfluramine separated by an interval of 14 days. Three further subjects received placebo on both days. Two hours after placebo/drug administration, 250 MBq of the 5-HT(2A) receptor selective PET-radiotracer [(18)F]altanserin was administered intravenously as a 30s bolus. Dynamic PET data were subsequently acquired over 90 min. Moreover, arterial blood samples were drawn for measurement of total activity and metabolite correction of the input function. Dexfenfluramine as well as cortisol and prolactin plasma concentration-time profiles was quantitatively determined. Tracer distribution volumes for five volumes-of-interest (prefrontal and occipital cortex, insula, thalamus, caudatum) were calculated by the Logan plot and a 2-tissue compartment model. Dexfenfluramine dose-dependently decreased the total distribution volume of [(18)F]altanserin in cortical regions independent of the PET modeling approach. Cortisol and prolactin plasma concentrations were dose-dependently increased by dexfenfluramine. The decrease in cortical [(18)F]altanserin receptor binding under dexfenfluramine was correlated with the increase of plasma prolactin. These data suggest that the combination of a dexfenfluramine-induced 5-HT release and subsequent assessment of 5-HT(2A) receptor availability with [(18)F]altanserin PET is suitable to measure cortical 5-HT release capacity in the human brain.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996132     DOI: 10.1016/j.neuroimage.2011.09.045

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  13 in total

1.  Cerebral serotonin release correlates with [11C]AZ10419369 PET measures of 5-HT1B receptor binding in the pig brain.

Authors:  Louise M Jørgensen; Pia Weikop; Claus Svarer; Ling Feng; Sune H Keller; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2017-07-07       Impact factor: 6.200

2.  Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36.

Authors:  Anders Ettrup; Sophie da Cunha-Bang; Brenda McMahon; Szabolcs Lehel; Agnete Dyssegaard; Anine W Skibsted; Louise M Jørgensen; Martin Hansen; Anders O Baandrup; Søren Bache; Claus Svarer; Jesper L Kristensen; Nic Gillings; Jacob Madsen; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-30       Impact factor: 6.200

Review 3.  PET Neurochemical Imaging Modes.

Authors:  Michael S Placzek; Wenjun Zhao; Hsiao-Ying Wey; Thomas M Morin; Jacob M Hooker
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

4.  Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain.

Authors:  Louise M Jørgensen; Pia Weikop; Jonas Villadsen; Tanel Visnapuu; Anders Ettrup; Hanne D Hansen; Anders O Baandrup; Flemming L Andersen; Carsten R Bjarkam; Carsten Thomsen; Bo Jespersen; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

5.  Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.

Authors:  Oliver G Bosch; Michael Wagner; Frank Jessen; Kai-Uwe Kühn; Alexius Joe; Erich Seifritz; Wolfgang Maier; Hans-Jürgen Biersack; Boris B Quednow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

6.  Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: potential involvement of endogenous morphine in the pathophysiology of schizophrenia.

Authors:  George B Stefano; Milena Králíčková; Radek Ptacek; Hana Kuzelova; Tobias Esch; Richard M Kream
Journal:  Med Sci Monit       Date:  2012-07

Review 7.  Molecular imaging as a guide for the treatment of central nervous system disorders.

Authors:  Euitae Kim; Oliver D Howes; Shitij Kapur
Journal:  Dialogues Clin Neurosci       Date:  2013-09       Impact factor: 5.986

Review 8.  Fluorine-18 radiochemistry, labeling strategies and synthetic routes.

Authors:  Orit Jacobson; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2014-12-12       Impact factor: 4.774

9.  Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge.

Authors:  David Erritzoe; Abhishekh H Ashok; Graham E Searle; Alessandro Colasanti; Samuel Turton; Yvonne Lewis; Mickael Huiban; Sara Moz; Jan Passchier; Azeem Saleem; John Beaver; Anne Lingford-Hughes; David J Nutt; Oliver D Howes; Roger N Gunn; Gitte M Knudsen; Eugenii A Rabiner
Journal:  Neuropsychopharmacology       Date:  2019-11-12       Impact factor: 8.294

10.  The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant schizophrenic negative symptoms.

Authors:  Christine Wyss; Konrad Hitz; Michael P Hengartner; Anastasia Theodoridou; Caitriona Obermann; Idun Uhl; Patrik Roser; Edna Grünblatt; Erich Seifritz; Georg Juckel; Wolfram Kawohl
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.